Back Other Health News

Other Infections

ASM Microbe 2016: Novel Immune Therapy GEN-003 Improves Genital Herpes

GEN-003, a therapeutic vaccine containing recombinant herpes simplex virus (HSV) antigens, showed significant antiviral activity lasting up to a year and reduced the number of genital herpes lesions and days with recurrences, researchers reported this week at the ASM Microbe 2016 meeting in Boston.

alt

Read more:

FDA Approves First Long-Lasting Buprenorphine Implant for Opioid Maintenance Therapy

The U.S. Food and Drug Administration last month approved the first-ever buprenorphine implant -- to be marketed under the brand name Probuphine -- which provides a steady dose of the drug over 6 months for people who are receiving opioid substitution therapy to manage dependence or addiction.

alt

Read more:

EASL 2016: NorUrsodeoxycholic Acid Help Rare Bile Duct Disease with No Current Treatment

A Phase 2 European trial showed that norUrsodeoxycholic acid leads to a significant reduction in serum alkaline phosphatase in people with primary sclerosing cholangitis (PSC), a rare but serious bile duct disease, according to a report presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.

alt

Read more:

ASCO 2016: PD-1 Blocker Nivolumab Shows Promise for Advanced Anal Cancer

The checkpoint inhibitor nivolumab(Opdivo), a monoclonal antibody targeting the PD-1 receptor, demonstrated activity against metastatic anal cancer that in patients who did not respond to prior treatment, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago. 70% of participants in this small study experienced complete or partial response or stabilized disease.

alt

Read more:

Hydromorphone as Effective as Pharmaceutical Heroin for Managing Opioid Dependence

Hydromorphone and pharmaceutical-grade heroin (diacetylmorphine) are both equally effective for the management of chronic heroin addiction among people who have not previously benefitted from medication-assisted treatment using methadone or buprenorphine, according to results from the SALOME study published in the April 6 online edition of JAMA Psychiatry.

alt

Read more:

WHO Recommends New Test and Shorter Treatment for Tuberculosis

The World Health Organization (WHO) this month released updated recommendations for a new test that can diagnose multidrug-resistant tuberculosis (MDR-TB) more rapidly, and a shorter and less expensive antibacterial regimen that can successfully treat resistant TB in 9 to 12 months.

alt

Read more:

CROI 2016: Large-Scale Household Tuberculosis Screening Shows Feasibility in PopART Trial

Offering tuberculosis (TB) screening as part of a home-based HIV testing intervention has the potential to identify numerous TB cases that would otherwise have gone undiagnosed, a report from a large community-based study in Zambia shows. The findings, from the PopART study, were reported by Comfort Phiri of Zambart at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston.

alt

Read more:

EASL 2016: Emricasan May Improve Inflammation and Liver Function in People with Cirrhosis

The novel caspase inhibitor emricasan (IDN-6556) led to improvements in various biomarkers and decreases in MELD scores in patients with liver cirrhosis due to hepatitis C, heavy alcohol use, or other causes, which significant declines among those who started with worse liver dysfunction, according to a late-breaking presentation at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.

alt

Read more:

CROI 2016: South Africa XDR-TB Epidemic Due to Transmission Rather than Viral Evolution

A study in KwaZulu-Natal, South Africa, evaluating the social networks as well as clinical and genotypic data from individuals with extensively drug resistant tuberculosis (XDR-TB)has concluded that transmission -- in both hospitals and households -- has been the primary driver of the XDR-TB epidemic in the province, according to a presentation at the annual Conference on Retroviruses and Opportunistic Infections (CROI 2016) last week in Boston.

alt

Read more: